<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-5256</journal-id>
<journal-title><![CDATA[Revista Med]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Med]]></abbrev-journal-title>
<issn>0121-5256</issn>
<publisher>
<publisher-name><![CDATA[Universidad Militar Nueva Granada. Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-52562023000100059</article-id>
<article-id pub-id-type="doi">10.18359/rmed.6408</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tendencias de la evidencia científica de las evaluaciones económicas y las enfermedades no transmisibles: un análisis bibliométrico]]></article-title>
<article-title xml:lang="en"><![CDATA[Trends in Scientific Evidence of Economic Evaluations and NonCommunicable Diseases: A Bibliometric Analysis]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tendências da evidência científica em avaliações econômicas e doenças não transmissíveis: uma análise bibliométrica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cubillos Osorio]]></surname>
<given-names><![CDATA[Astrid Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palencia-Sánchez]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Riaño-Casallas]]></surname>
<given-names><![CDATA[Martha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>31</volume>
<numero>1</numero>
<fpage>59</fpage>
<lpage>74</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-52562023000100059&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-52562023000100059&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-52562023000100059&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: el envejecimiento de la población a nivel global ha generado un creciente interés en el estudio de las Enfermedades No Transmisibles (ENT) y la necesidad de evaluar económicamente su abordaje, dado su impacto en la mortalidad. El objetivo de este estudio es analizar la producción científica de evaluaciones económicas de las ENT y detectar áreas de investigación menos exploradas. Se llevó a cabo una búsqueda de la literatura en Web of Science (WoS), PubMed y Scopus. Se utilizó R/Bibliometrix y VosViewer para el análisis de datos. Los resultados revelaron un incremento en la producción científica a lo largo del tiempo. La revista &#8220;Value in Health&#8221; se destacó por ser la que más publicaciones ha realizado y los autores Mark Lamotte y Lieven Annemans fueron los que más publicaron. Los principales nodos de información estuvieron relacionados con diabetes en las ENT y con carga de enfermedad y costo-efectividad en las evaluaciones económicas. En conclusión, la producción científica relacionada con las evaluaciones económicas de las ENT se enfoca predominantemente en el análisis de los costos directos asociados a estas enfermedades y a los subanálisis de los Estudios de la Carga Global de Enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: The global aging population has sparked growing interest in the study of NonCommunicable Diseases (NCDS) and the necessity of economically evaluating their management due to their impact on mortality. This study aims to analyze the scientific production of economic evaluations regarding NCDS and identify less explored research areas. A literature search was conducted on Web of Science (WoS), PubMed, and Scopus. R/Bibliometrix and VosViewer were utilized for data analysis. Results revealed a consistent increase in scientific production over time. The journal &#8220;Value in Health&#8221; stood out for its extensive publications, and authors Mark Lamotte and Lieven Annemans were among the most prolific contributors. Main information nodes were associated with diabetes in NCDS and disease burden, and cost-effectiveness in economic evaluations. In conclusion, scientific production related to economic evaluations of NCDS predominantly focuses on analyzing direct costs associated with these diseases and sub-analyses ofGlobal Burden of Disease Studies.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: O envelhecimento da população em nível global tem suscitado um crescente interesse no estudo das Doenças Não Transmissíveis (DNT) e na necessidade de avaliar economicamente sua abordagem, devido ao impacto na mortalidade. O objetivo deste estudo é analisar a produção científica de avaliações econômicas das DNT e identificar áreas de pesquisa menos exploradas. Foi realizada uma busca de literatura nas bases de dados Web of Science (WoS), PubMed e Scopus. Para a análise dos dados, foram utilizadas as ferramentas R/Bibliometrix e VosViewer. Os resultados revelaram um aumento na produção científica ao longo do tempo. A revista &#8220;Value in Health&#8221; destacou-se como a que mais publicou nessa área, e os autores Mark Lamotte e Lieven Annemans foram os que mais publicaram. Os principais tópicos de informação estavam relacionados à diabetes entre as DNT, bem como à carga de doença e à análise de custo-efetividade em avaliações econômicas. Em conclusão, a produção científica relacionada às avaliações econômicas das DNT concentra-se predominantemente na análise dos custos diretos associados a essas doenças e nas subanálises dos Estudos de Carga Global de Doenças.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[evaluación económica]]></kwd>
<kwd lng="es"><![CDATA[enfermedades no transmisibles]]></kwd>
<kwd lng="es"><![CDATA[costos y análisis de costo]]></kwd>
<kwd lng="es"><![CDATA[carga global de enfermedades]]></kwd>
<kwd lng="en"><![CDATA[Economic Evaluation]]></kwd>
<kwd lng="en"><![CDATA[Non-Communicable Diseases]]></kwd>
<kwd lng="en"><![CDATA[Cost and Cost Analysis]]></kwd>
<kwd lng="en"><![CDATA[Global Disease Burden]]></kwd>
<kwd lng="pt"><![CDATA[avaliação econômica]]></kwd>
<kwd lng="pt"><![CDATA[doenças não transmissíveis]]></kwd>
<kwd lng="pt"><![CDATA[custos e análise de custo]]></kwd>
<kwd lng="pt"><![CDATA[carga global de doenças]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>United Nations, Department of Economic and Social Affairs</collab>
<source><![CDATA[World Population Prospects 2019: Highlights]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vollset]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility, Mortality, Migration, and Population Scenarios for 195 Countries and Territories from 2017 to 2100: A Forecasting Analysis for the Global Burden of Disease Study]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2020</year>
<volume>396</volume>
<numero>10258</numero>
<issue>10258</issue>
<page-range>1285-306</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[AJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Longevity Society]]></article-title>
<source><![CDATA[The Lancet Healthy Longevity]]></source>
<year>2021</year>
<volume>2</volume>
<page-range>e820-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[The top 10 Causes of Death]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Etienne]]></surname>
<given-names><![CDATA[CF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Promover la información sobre la economía de las enfermedades no transmisibles en la Región de las Américas*]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2018</year>
<volume>42</volume>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Likhar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Alok]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of Economic Evaluation in Health Care: An Indian Perspective]]></article-title>
<source><![CDATA[Value Health Reg Issues]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>78-83</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morillo]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Epidemiología clínica: investigación clínica aplicada]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yousefi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Household Health Costs: Direct, Indirect, and Intangible]]></article-title>
<source><![CDATA[Iran J Public Health]]></source>
<year>2014</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>202-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donthu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to Conduct a Bibliometric Analysis: An Overview and Guidelines]]></article-title>
<source><![CDATA[J Bus Res]]></source>
<year>2021</year>
<volume>133</volume>
<page-range>285-96</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Eck]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Waltman]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Software Survey: VOSviewer, a Computer Program for Bibliometric Mapping]]></article-title>
<source><![CDATA[Scientometrics]]></source>
<year>2010</year>
<volume>84</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>523-38</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salinas]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<source><![CDATA[Bibliometrix: Primeros pasos y técnicas avanzadas con BiblioShiny App]]></source>
<year>2020</year>
<publisher-name><![CDATA[Zenodo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cuccurullo]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bibliometrix: An R-tool for Comprehensive Science Mapping Analysis]]></article-title>
<source><![CDATA[J Informetr]]></source>
<year>2017</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>959-75</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mulugeta]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disease Burdens and Risk Factors for Diabetes, Hypertension, and Hyperlipidemia among Refugees in Buffalo, New York, 2004-2014]]></article-title>
<source><![CDATA[J Health Care Poor Underserved]]></source>
<year>2019</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1119-31</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries with Diabetes, 1999-2017]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2021</year>
<volume>44</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1797-804</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[National Trends in Out-of-Pocket Costs Among U.S. Adults with Diabetes Aged 18-64 Years: 2001-2017]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2021</year>
<volume>44</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2510-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-utility of Afatinib and Gefitinib as First-Line Treatment for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer]]></article-title>
<source><![CDATA[Future Oncol]]></source>
<year>2019</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>181-91</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US]]></article-title>
<source><![CDATA[Front Public Health]]></source>
<year>2021</year>
<volume>9</volume>
<page-range>650392</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wimo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Economic Evaluation of Donepezil in Mild to moderate Alzheimer&#8217;s Disease: Results of a 1-year, Double-Blind, Randomized Trial [published correction appears in Dement Geriatr Cogn Disord. 2003;16(2):102]]]></article-title>
<source><![CDATA[Dement Geriatr Cogn Disord]]></source>
<year>2003</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-54</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wimo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resource Utilization and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer&#8217;s Disease]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2003</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>327-40</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Handels]]></surname>
<given-names><![CDATA[RLH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-Utility of Using Alzheimer&#8217;s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia]]></article-title>
<source><![CDATA[J Alzheimers Dis]]></source>
<year>2017</year>
<volume>60</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1477-87</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Handels]]></surname>
<given-names><![CDATA[RLH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early Cost-Utility Analysis of General and Cerebrospinal Fluid-specific Alzheimer&#8217;s Disease Biomarkers for Hypothetical Disease-Modifying Treatment Decision in Mild Cognitive Impairment]]></article-title>
<source><![CDATA[Alzheimer&#8217;s &amp; Dementia]]></source>
<year>2015</year>
<volume>11</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>896-905</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vossius]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost Analysis of Day Care Centres in Norway]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2019</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wimo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-utility Analysis of Group Living in Dementia Care]]></article-title>
<source><![CDATA[Int J Technol Assess Health Care]]></source>
<year>1995</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-65</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robles-Zurita]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic Evaluation of Culprit Lesion only PCI vs. immediate Multivessel PCI in Acute Myocardial Infarction Complicated by Cardiogenic Shock: the Culprit-Shock Trial]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2020</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1197-209</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolowacz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and Validation of a Cost-Utility Model for Type 1 Diabetes Mellitus]]></article-title>
<source><![CDATA[Diabet Med]]></source>
<year>2015</year>
<volume>32</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1023-35</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health Related Quality of Life Utility Weights for Economic Evaluation through Different Stages of Chronic Kidney Disease: a Systematic Literature Review]]></article-title>
<source><![CDATA[Health Qual Life Outcomes]]></source>
<year>2020</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>310</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 Diabetes Remission: Economic Evaluation of the DiRECT/Counterweight-Plus Weight Management Programme within a Primary Care Randomized Controlled Trial]]></article-title>
<source><![CDATA[Diabet Med]]></source>
<year>2019</year>
<volume>36</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1003-12</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamotte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2006</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-69</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Annemans]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health Economic Evaluation of Controlled and Maintained Physical Exercise in the Prevention of Cardiovascular and other Prosperity Diseases]]></article-title>
<source><![CDATA[Eur J Cardiovasc Prev Rehabil]]></source>
<year>2007</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>815-24</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsutani]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan]]></article-title>
<source><![CDATA[Intern Med]]></source>
<year>2007</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>157-62</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Economic Evaluation based on a Randomized Placebo-Controlled Trial of Varenicline in Smokers with Cardiovascular Disease: Results for Belgium, Spain, Portugal, and Italy]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2012</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1173-83</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotseva]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient and Caregiver Productivity Loss and Indirect Costs Associated with Cardiovascular Events in Europe]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2019</year>
<volume>26</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1150-7</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<collab>GBD 2017 DALYs and HALE Collaborators</collab>
<article-title xml:lang=""><![CDATA[Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 359 Diseases and Injuries and Healthy Life Expectancy (HALE) for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10159</numero>
<issue>10159</issue>
<page-range>1859-922</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Theodoratou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of Published Economic Evaluations of Angiotensin Receptor Blockers]]></article-title>
<source><![CDATA[Hellenic J Cardiol]]></source>
<year>2009</year>
<volume>50</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-18</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maniadakis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic Evaluation of Irbesartan in Combination with Hydrochlorothiazide in the Treatment of Hypertension in Greece]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2011</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>253-61</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fragoulakis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kourlaba]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maniadakis]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic Evaluation of Statins in High-risk Patients Treated for Primary and Secondary Prevention of Cardiovascular Disease in Greece]]></article-title>
<source><![CDATA[Clinicoecon Outcomes Res]]></source>
<year>2012</year>
<volume>4</volume>
<page-range>135-43</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of Detemir-Based Basal/Bolus Therapy versus NPH-based Basal/Bolus Therapy for Type 1 diabetes in a UK Setting:An Economic Analysis Based on Meta-Analysis Results of four Clinical Trials]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2004</year>
<volume>20</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1729-46</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sivignon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-economic Evaluation of Lung Cancer Drugs: do s and don ts in France]]></article-title>
<source><![CDATA[Value in Health]]></source>
<year>2019</year>
<volume>22</volume>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamotte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Health Economic Evaluation of Concomitant Surgical Ablation for Atrial Fibrillation]]></article-title>
<source><![CDATA[Eur J Cardiothorac Surg]]></source>
<year>2007</year>
<volume>32</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>702-10</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<collab>GBD 2017 DALYs and HALE Collaborators</collab>
<article-title xml:lang=""><![CDATA[Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 359 Diseases and Injuries and Healthy Life Expectancy (HALE) for 195 Countries And Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10159</numero>
<issue>10159</issue>
<page-range>1859-922</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<collab>GBD 2013 DALYs and HALE Collaborators</collab>
<article-title xml:lang=""><![CDATA[Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 306 Diseases and Injuries and Healthy Life Expectancy (HALE) for 188 countries, 1990-2013: Quantifying the Epidemiological Transition]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>10009</numero>
<issue>10009</issue>
<page-range>2145-91</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<collab>GBD 2015 DALYs and HALE Collaborators</collab>
<article-title xml:lang=""><![CDATA[Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017 Jan 7;389(10064):e1]]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10053</numero>
<issue>10053</issue>
<page-range>1603-58</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<collab>GBD 2015 DALYs and HALE Collaborators</collab>
<article-title xml:lang=""><![CDATA[Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015]]></article-title>
<source><![CDATA[[published correction appears in Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10064</numero>
<issue>10064</issue>
<page-range>1603-58</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disability-adjusted Life Years (DALYs) for 291 Diseases and Injuries in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010]]></article-title>
<source><![CDATA[[published correction appears in Lancet. [Internet]]]></source>
<year>2013</year>
<volume>380</volume>
<numero>9859</numero>
<issue>9859</issue>
<page-range>2197-223</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aghaei Chadegani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Comparison Between two Main Academic Literature Collections: Web of Science and Scopus Databases]]></article-title>
<source><![CDATA[Asian Social Science]]></source>
<year>2013</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>18-26</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Tale of two Databases: the use of Web of Science and Scopus in Academic Papers]]></article-title>
<source><![CDATA[Scientometrics]]></source>
<year>2020</year>
<volume>123</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>321-35</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="">
<collab>National Center for Biotechnology information (NCBI)</collab>
<source><![CDATA[National Library of Medicine. PubMed]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Economic Evaluation of Irbesartan in the Treatment of Patients with type 2 Diabetes, Hypertension and Nephropathy: Cost-Effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2003</year>
<volume>18</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2059-66</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<collab>World University Rankings</collab>
<source><![CDATA[QS World University Rankings 2022: Top Global Universities | Top Universities]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[PAE]]></given-names>
</name>
<name>
<surname><![CDATA[Casallas]]></surname>
<given-names><![CDATA[MIR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación entre felicidad en el trabajo y desempeño laboral: análisis bibliométrico, evolución y tendencias]]></article-title>
<source><![CDATA[Revista Virtual Universidad Católica del Norte]]></source>
<year>2021</year>
<volume>64</volume>
<page-range>241-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
